This invention provides an isolated monoclonal antibody that binds to CD47 or an immunologically active fragment thereof, wherein the antibody does not cause a significant level of agglutination of cells after administration. The invention further provides the antibody or an immunologically active fragment thereof for use in a method of alleviating a symptom of a cancer or other neoplastic condition. The invention also provides a pharmaceutical composition comprising the antibody or immunologically active fragment thereof and a carrier.